F-star Therapeutics, Inc.
FSTX · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,125 | $0 | $2,551 | $17,499 |
| % Growth | – | -100% | -85.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,125 | $0 | $2,551 | $17,499 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $9,670 | $8,724 | $8,037 | $8,214 |
| G&A Expenses | $5,161 | $7,457 | $5,702 | $4,962 |
| SG&A Expenses | $5,161 | $7,457 | $5,702 | $4,962 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,831 | $16,181 | $13,739 | $13,176 |
| Operating Income | -$13,706 | -$16,181 | -$11,188 | $4,179 |
| % Margin | -1,218.3% | – | -438.6% | 23.9% |
| Other Income/Exp. Net | -$4,701 | -$2,813 | -$899 | $285 |
| Pre-Tax Income | -$18,407 | -$18,994 | -$12,087 | $4,179 |
| Tax Expense | $60 | $127 | $58 | -$562 |
| Net Income | -$18,467 | -$19,121 | -$12,145 | $4,741 |
| % Margin | -1,641.5% | – | -476.1% | 27.1% |
| EPS | -0.84 | -0.89 | -0.58 | 0.23 |
| % Growth | 5.6% | -53.4% | -352.2% | – |
| EPS Diluted | -0.84 | -0.89 | -0.58 | 0.23 |
| Weighted Avg Shares Out | 21,856 | 21,573 | 21,083 | 20,618 |
| Weighted Avg Shares Out Dil | 21,856 | 21,573 | 21,083 | 20,618 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $378 | $334 | $308 | -$844 |
| Depreciation & Amortization | -$4,074 | -$2,198 | -$346 | -$607 |
| EBITDA | -$17,780 | -$18,379 | -$11,534 | $3,572 |
| % Margin | -1,580.4% | – | -452.1% | 20.4% |